Determining The Incidence Of Dengue In Ile-ife

DETERMINING THE INCIDENCE OF DENGUE IN ILE-IFE

Type: Project
Department: Microbiology
Project ID: MCB0325
Access Fee: ₦5,000 ($14)
Pages: 39 Pages
Format: Microsoft Word
Views: 347
Report This work

Pyrexia of unknown origin (PUO) is fever that occurs for no apparent reason with failure toestablish diagnosis within one week of investigation. The fever involves temperatures ofgreater than 38.3oC which occurs sporadically for more than three weeks. Fever resolvesusually after about 3 days but can take 2 weeks.

Dengue is a tropical mosquito borne-viral disease and is marked by high fever and severe muscle and joint pains. It is caused by any of four antigenically and genetically distinct viruses of the family flaviviridae, named denv-1, denv-2, denv-3 and denv-4 (Craven, 1991). It is therefore possible to get dengue fever multiple times, as an attack of dengue produces lifetime immunity to that particular serotype to which the patient was exposed. Humans are the primary vertebrate host of these viruses, although there is evidence of a silent zoonotic cycle involving monkeys in parts of Asia and Africa (Cordellier et al., 1983).

Dengue fever is characterized by an abrupt onset of fever, headache, myalgia, loss of appetite and varying gastrointestinal symptoms often accompanied by bone and joint pains (Ehrenkranzetal., 1979). Symptoms persist for 3–7 days, and while convalescence may be prolonged for several weeks, mortality is rare. Homologous immunity is lifelong, but cross-protection to other dengue viruses is not elicited and, indeed, there is evidence to suggest that heterologous antibodies may form infectious immune complexes which may increase the severity of subsequent infections (Kliks et al., 1989).

Dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) are more severe manifestations of dengue infection, and are most often associated with infection of people with pre-existing antibodies to dengue, either passively or actively acquired i.e. antibody dependent enhancement (Halstead et al., 1980).

INTRODUCTION                    1
1.2 Aims and Objectives        3
2.2 The Dengue Virus            6
2.2.1 Replication Cycle           7
2.3 Epidemiology                    9
2.3.1 Outbreaks of Dengue fever in West Africa    12
2.4.2 Laboratory Diagnosis    13
2.5 Transmission                    14
2.6 Pathogenesis                    15
2.6.1. Prognosis                      16
2.6.2.2 Dengue Shock Syndrome (DSS)            18
2.7 Treatment                         19
2.8.2 Mosquito Control             21
2.8.3 Control of Outbreak         22
3.2 Materials                             23
3.3 Principle of the Test           24
3.4 Sample Collection                25
3.5 Test Procedure                    25
3.6 Safety Considerations        27
4.1 Anti-Dengue IgM antibody and age distribution    28
4.2 Anti-Dengue IgM antibody and sex distribution    30
4.3 Anti-Dengue IgM antibody and Malaria parasite tests results    32
REFERENCES

DETERMINING THE INCIDENCE OF DENGUE IN ILE-IFE

For more Info, call us on
+234 8130 686 500
or
+234 8093 423 853

Bank	GTBANK
Account Name	Obiaks Business Venture
Account Number	0211074565

Bank payment for Nigerians, Make a payment of ₦ 5,000 to

Bitcoin: Make a payment of 0.0005 to

Bitcoin(Btc)

Details

Related Works

Quick Navigation Menu

Type	Project
Department	Microbiology
Project ID	MCB0325
Fee	₦5,000 ($14)
No of Pages	39 Pages
Format	Microsoft Word


Copy to clipboard Copy text